https://doi.org/10.1016/j.mam.2023.101204
Highlights
- •Tumors from Lynch syndrome patients have high mutation and neoantigen burden, which leads to high infiltration of T-cells.
- •Certain tumor neoantigens are shared among Lynch syndrome patients due to mutations recurring in prone microsatellite loci.
- •Several in silico tools have emerged to predict neoantigens and their immunogenicity from next-generation sequencing data.
- •Lynch Syndrome patients are a defined and prevalent population with potential to benefit from cancer immune-interception.
- •Neoantigen-based vaccines hold promise for the treatment and potential prevention of mismatch repair deficient cancers.
Lynch Syndrome Ireland 